Active, not recruitingPhase 4NCT05160922
Crizotinib Continuation Clinical Study
Studying ALK-negative anaplastic large cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- crizotinib(drug)
- Enrollment
- 27 enrolled
- Eligibility
- 0 years · All sexes
- Timeline
- 2021 – 2028
Study locations (13)
- Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing Municipality, China
- Beijing Cancer Hospital, Beijing, Beijing Municipality, China
- Fujian Province Oncology Hospital, Fuzhou, Fujian, China
- Sun Yat-Sen University Cancer center, Guangzhou, Guangdong, China
- The First Affiliated Hospital of Guangzhou Medical University., Guangzhou, Guangzhou, China
- Jilin Cancer Hospital, Changchun, Jilin, China
- West China Hospital of Sichuan University, Wuhou District, Sichuan, China
- The First Affiliated Hospital of College of Medicine,Zhejiang University, Hangzhou, Zhejiang, China
- Shanghai Chest Hospital, Shanghai, China
- ASST Monza, Monza, MB, Italy
- National Hospital Organization Nagoya Medical Center, Nagoya, Aichi-ken, Japan
- Limited Liability Company "EuroCityClinic", Saint Petersburg, Russia
- National Taiwan University Hospital, Taipei, Taiwan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05160922 on ClinicalTrials.govOther trials for ALK-negative anaplastic large cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07300514Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell LymphomaFudan University
- RECRUITINGPHASE2NCT07356245Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaJonathan Brammer
- RECRUITINGPHASE1NCT06176690Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive LymphomasBaylor College of Medicine
- RECRUITINGPHASE1NCT07001384A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)Memorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT07013565Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCLNew York Medical College
- RECRUITINGPHASE2NCT05996185Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell LymphomaYale University
- RECRUITINGPHASE1NCT06508463Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaMayo Clinic
- RECRUITINGPHASE1, PHASE2NCT04925609Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid TumorsPrincess Maxima Center for Pediatric Oncology
See all trials for ALK-negative anaplastic large cell lymphoma →